Stock Events

Stock Events

Oramed Pharmaceuticals 

$3.52
0
+$0+0% Today

Statistics

Day High
3.52
Day Low
3.38
52W High
-
52W Low
-
Volume
80
Avg. Volume
-
Mkt Cap
140.1M
P/E Ratio
-
Dividend Yield
7.4%
Dividend
0.26

Upcoming

18
JAN 27
Dividend Ex
Estimated
 
28
JAN 27
Dividend Payment
Estimated
 
17
JAN 28
Dividend Ex
Estimated
 
27
JAN 28
Dividend Payment
Estimated
 

Dividends

7.4%Dividend Yield
Jan 26
$0.25
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-0.08
-0.05
-0.03
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-38.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORMP.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Oramed's oral insulin capsule.
Mannkind
MNKD
Mkt Cap1.72B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes, such as Afrezza, competing in the diabetes management space.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a multinational pharmaceutical company that offers a range of diabetes solutions, including insulin products, competing in the same therapeutic area as Oramed.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company is a global healthcare leader that develops a wide range of pharmaceutical products, including treatments for diabetes, directly competing with Oramed's products.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that has a significant portfolio of diabetes treatments, competing in the same market as Oramed.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines, including for diabetes, which puts it in competition with Oramed.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers a broad range of diabetes treatments, including oral medications, directly competing with Oramed's oral insulin product.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, competing in the broader diabetes care market.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation is engaged in the development, manufacture, and sale of its Omnipod Insulin Management System, a competitor in the insulin delivery space.
Dexcom
DXCM
Mkt Cap22.71B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetes management, indirectly competing by offering alternative diabetes management solutions.

About

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Show more...
CEO
ISIN
US68403P2039

Listings

TA
IL
ORMP.TA
XNAS
US
ORMP
F
DE
OJU1.F
BOATS
BOATS
ORMP.BOATS

0 Comments

Share your thoughts

FAQ

What is Oramed Pharmaceuticals stock price today?▼
The current price of ORMP.BOATS is $3.52 USD — it has increased by +0% in the past 24 hours. Watch Oramed Pharmaceuticals stock price performance more closely on the chart.
What is Oramed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oramed Pharmaceuticals stocks are traded under the ticker ORMP.BOATS.
What is Oramed Pharmaceuticals market cap?▼
Today Oramed Pharmaceuticals has the market capitalization of 140.1M
When is the next Oramed Pharmaceuticals earnings date?▼
Oramed Pharmaceuticals is going to release the next earnings report on June 03, 2026.
What were Oramed Pharmaceuticals earnings last quarter?▼
ORMP.BOATS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.08 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oramed Pharmaceuticals revenue for the last year?▼
Oramed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Oramed Pharmaceuticals net income for the last year?▼
ORMP.BOATS net income for the last year is -38.12M USD.
Does Oramed Pharmaceuticals pay dividends?▼
Yes, ORMP.BOATS dividends are paid annual. The last dividend per share was 0.25 USD. As of today, Dividend Yield (FWD)% is 7.4%.
When did Oramed Pharmaceuticals complete a stock split?▼
Oramed Pharmaceuticals has not had any recent stock splits.